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Abstract 
AMP-activated protein kinase (AMPK), a phylogenetically conserved serine/threonine protein 
kinase, has been proposed to function as a 'fuel gauge' to monitor cellular energy status in 
response to nutritional environmental variations. AMPK system is a regulator of energy 
balance that, once activated by low energy status, switches on ATP-producing catabolic 
pathways (such as fatty acid oxidation and glycolysis), and switches off ATP-consuming 
anabolic pathways (such as lipogenesis), both by short-term effect on phosphorylation of 
regulatory proteins and by long-term effect on gene expression. Numerous observations 
obtained with pharmacological activators and agents that deplete intracellular ATP have been 
supportive of AMPK playing a role in the control of energy metabolism but none of these 
studies have provided conclusive evidence. Relatively recent developments in our 
understanding of precisely how AMPK complexes might operate to control energy 
metabolism is due in part to the development of transgenic and knockout mouse models. 
Although there are inevitable caveats with genetic models, some important findings have 
emerged. In the present review, we discuss recent findings obtained from animal models with 
inhibition or activation of AMPK signaling pathway. 
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Introduction 
To sustain metabolism, intracellular ATP concentration must be maintained within a narrow 
range. This is achieved both at the cellular level as well as the systemic level, encompassing 
intracellular regulation of anabolic and catabolic pathways in addition to substrate storage and 
release. It has been recently described how this co-ordination may be achieved through the 
functions of AMP-activated protein kinase (AMPK), a phylogenetically conserved 
serine/threonine protein kinase. AMPK has been viewed as a signal integrator monitoring 
systemic and cellular energy status (1). This kinase is typically, but not exclusively, activated 
by an increase AMP/ATP ratio. Once activated, AMPK regulates a large number of 
downstream targets, shutting down anabolic pathways and stimulating catabolic pathways, 
thus simultaneously sparing limited energy resources and acquiring extra energy. A 
synergistic response entails inhibition of anabolic pathways that mediate the synthesis of 
macromolecules such as protein, fatty acids, lipids, cholesterol and glycogen. Concomitantly 
AMPK stimulates energy providing pathways like β-oxidation, glucose uptake and cardiac 
glycolysis, the net result of AMPK activation being stabilisation of ATP levels and restoration 
of energy balance. AMPK acts first by directly affecting key enzymes activities, e.g. in 
glucose and fat metabolism, and second by longer-term transcriptional control of key players 
of these metabolic pathways. Important progress has recently been made in the understanding 
of the pathophysiological role of AMPK at both the cellular and whole organism level. This is 
in part due to the development of transgenic and knockout (KO) mouse models, which have 
made it possible to study distinct physiological functions for AMPK isoforms. 
 
 
Structure and function of AMPK complexes 
AMPK exists as a heterotrimeric complex consisting of a catalytic subunit α and two 
regulatory β and γ subunits (1). The conventional serine/threonine kinase activity of AMPK is 
supported by α subunit which is characterized by the presence in the activation loop of a 
threonine residue (Thr172) whose phosphorylation is required for activation. The C-terminal 
region of α subunit is required for the association with the other two β and γ subunits. The β 
subunit contains a C-terminal region required for the association with α and γ subunits and a 
central region that allowed AMPK complex to bind glycogen. The γ subunit contains four 
tandem repeats known as cystathionine β-synthase (CBS) motifs which bind, together, two 
molecules of AMP or ATP in a mutually exclusive manner. Binding of AMP (on γ subunit) 
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activates AMPK via a complex mechanism involving direct allosteric activation and 
phosphorylation of α subunit on Thr172 by upstream kinases as the protein kinase LKB1 (a 
tumour suppressor whose germline mutations in humans are the cause of Peutz-Jeghers 
syndrome), the CaMKKIIβ (calmodulin-dependent protein kinase kinase IIβ) and perhaps 
also TAK1 (mammalian transforming growth factor β-activated kinase) (1). Although it was 
originally proposed that AMP binding promoted AMPK phosphorylation by upstream 
kinases, recent works suggested that it occurs entirely by inhibiting dephosphorylation of 
Thr172, probably catalysed by protein phosphatase 2Cα (2, 3). 
Homologues of all three subunits have been identified in mammals, fruitfly (Drosophila 
melanogaster), worm (Caenorhabditis elegans), yeast (Saccharomyces cerevisiae), plants 
(Arabidopsis thaliana) and the primitive protozoon Giardia lamblia, with a high degree of 
conservation that suggests that this ancient signaling circuit evolved at least a billion years 
ago to regulate a wide spectrum of actions on metabolic homeostasis. In mammals, two to 
three isoforms of each subunit (α1, α2, β1, β2, γ1, γ2, γ3) encoded by different genes are 
known giving rise to a large variety of heterotrimeric combinations, with splice variants (for 
the γ2 and γ3 genes) adding to the diversity. Furthermore, differences in the tissue distribution 
of catalytic and regulatory isoforms expression patterns have been reported (1). Thus, recent 
investigation of isoform composition of AMPK complexes in human skeletal muscle found 
that only 3 of the 12 theoretically possible AMPK complexes were present 
(α2β2γ1>>α2β2γ3=α1β2γ1) and were activated differently depending on exercise intensity 
and duration (4-6). Moreover, a specificity of each catalytic isoforms for their preferentially 
upstream kinase has been clearly shown both in skeletal muscle (7) and heart (8). Indeed, in 
LKB1-/- mice, ischemia in the heart and contraction in skeletal muscle were no more able to 
activate AMPKα2 subunit whereas AMPKα1 activation is only slightly affected. 
Interestingly, expression of the γ3 subunit appeared highly specific to glycolytic skeletal 
muscle whereas γ1 and γ2 showed broad tissue distributions. In skeletal muscle, the β2 
subunit is also highly expressed but the β1 subunit predominates in the liver. AMPKα1 and 
α2-containing complexes account each for about half of total AMPK activity in liver. In 
adipose tissue, AMPK complexes containing the α1 catalytic subunit are mainly expressed 
whereas, in skeletal and cardiac muscles, AMPK complexes containing the α2 catalytic 
subunit are predominant. In addition of differences in tissue distribution, it is now accepted 
that AMPK complexes distribution is also regulated at the intracellular level. Indeed, 
AMPKα2-containing complexes were found in both the nucleus and the cytoplasm raising the 
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possibility of the direct phosphorylation of co-activators and transcription factors (9, 10). In 
contrast, AMPKα1-containing complexes are predominantly localized in the cytoplasm but 
have been also observed at the plasma membrane in airway epithelial cells (11) and carotid 
body cells (12). Although the functional significance of different AMPK isoform combination 
remains unclear, it raised important questions about the function of each heterotrimeric 
AMPK complex in relation with their particular sensitivity to AMP and ATP, subcellular 
localization and/or specific targets (13). As a matter of fact, it has been hypothesized that 
regulation of exercise-induced glucose transport in human skeletal muscle could be rather 
associated with α2β2γ1 than α2β2γ3 heterotrimeric complex activation (6). Recently, it has 
been suggested that isoform combination may also determine subcellular targeting of AMPK 
and hence targeting substrates. Very fascinatingly, it has been demonstrated that post-
translational modification of the β1 subunit may target AMPK complexes to the plasma 
membrane (14). In addition, it was found that plectin, a cytoskeleton linker protein which has 
been shown to bind the γ1 subunit, affects the subunit composition of AMPK complexes in 
differentiated myotubes (15). Thus, the selective expression of a particular heterotrimeric 
AMPK complex could determine a specialized cellular and systemic response to different 
metabolic stresses. 
 
 
Development of animal models for the study of AMPK functions 
As most of the action of AMPK has been described on the basis of incubation of eukaryotic 
cells with pharmacological activators of AMPK such as 5-aminoimidazole-4-carboxamide 
riboside (AICAR) and the antidiabetic drug metformin (16), it has been difficult to assign 
specific functions for AMPK heterotrimeric complexes since pharmacological activation of 
AMPK would supposedly concern all AMPK complexes. To answer this question, the use of 
mouse transgenic and KO models (Table 1A and 1B) has proved useful in this respect. The 
generation of catalytic subunit (α1-/- and α2-/-) knockout animals has emphasized the distinct 
and critical role for AMPKα1 and AMPKα2 catalytic subunit in the control of energy 
metabolism. Unfortunately, a double knockout is embryonic lethal at ∼10.5 days post-
conception (BV, unpublished results), but the development of tissue-specific and conditional 
knockout for AMPKα2 isoform has allowed the generation of animal models completely 
lacking hepatic AMPK activity (AMPKα1α2LS-/- mice) by crossing liver-specific AMPKα2-
/- mice with AMPKα1-/- mice. In addition, conditional knockout for AMPKα1 isoform are 
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also now being generated (BV and MF, unpublished results) and will allow the establishment 
of tissue-specific deletion of both AMPKα1 and α2 catalytic subunits in the near future. 
Another approach to suppress AMPK activity in vivo is the generation of transgenic mice 
over-expressing a kinase-inactive mutant α subunit acting as a dominant-negative form. This 
strategy has been used to inhibit AMPK in heart and skeletal muscle. Genetic models with 
deletion of the β subunit isoforms of AMPK have been recently generated and have revealed 
that AMPK β subunits are unable to compensate for the loss of each other at least in liver and 
skeletal muscle (B. Kemp, personal communication). Ablation of AMPKγ3 subunit 
expression has also been realized making available another model with an altered AMPK 
signaling pathway in skeletal muscle. Furthermore, the introduction of transgenic mouse 
models involving the γ isoforms harbouring naturally occurring mutations in human γ2 and 
pig γ3, leading to metabolic abnormalities in heart and skeletal muscle, respectively, has 
enhanced our understanding of AMPK signaling in these tissues. Animal models over-
expressing constitutively active forms of AMPK (mutated form of the α2 or γ1 subunit) in 
liver and skeletal muscle have been also generated and provide useful models for the study of 
acute and chronic activation of AMPK. In addition to all these mammalian genetic models, 
the consequence of AMPK deletion or over-expression in the C. elegans and Drosophila 
model systems has been described very recently and gain insight into the multiple roles of 
AMPK in the regulation of energy metabolism and other physiological processes. 
 
Distinct physiological roles for α1/α2 catalytic subunits of AMPK in the control of whole-
body energy metabolism and insulin sensitivity 
Important progress has recently been made in the understanding of distinct physiological 
functions for AMPKα subunits thanks to the metabolic exploration of AMPKα1-/- and 
AMPKα2-/- mice (17, 18). An important issue was to investigate the specific targets and roles 
for α1 and α2 catalytic subunits. To firstly examine this point, AICAR tolerance tests were 
performed in both AMPKα1-/- and AMPKα2-/- mice. Interestingly, AMPKα2-/- but not 
AMPKα1-/-mice are resistant to hypoglycemic AICAR effects (17, 18) suggesting that 
AMPKα2-containing complexes are the main contributors of AMPK activation during 
AICAR stimulation at the whole-body level. This is remarkable if we consider that both 
catalytic subunits are present in the most important tissues (as skeletal muscle and liver) for 
the regulation of glucose homeostasis. Thus, if AMPKα2-/- mice are resistant to AICAR 
hypoglycemic action, this suggested that remaining complexes containing AMPKα1 could 
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not fully compensate for the lack of AMPKα2. Furthermore, no experimental data (and 
especially from in vitro studies) suggested that sensitivity to AMP (or ZMP) would be 
modulated by isoform composition of AMPK complexes. Discrepancy between α1 and α2 
catalytic subunits not only concerns AICAR hypoglycemic action. Indeed, whole-body 
deletion of AMPKα1 has no detectable metabolic phenotype whereas whole-body AMPKα2 
deletion results in mild insulin-resistance and in impaired glucose tolerance associated with 
insulin secretory defect (17, 18). These metabolic alterations are both features of type 2 
diabetes and emphasize AMPKα2-/- mice as a new animal model of this disease. But, in 
contrast to the multiple defects in intracellular insulin pathway observed in type 2 diabetes, 
AMPKα2-/- mice do not display typical features of this disease at a molecular level. In 
particular, insulin release by isolated pancreatic islets and insulin-stimulated glucose uptake 
by isolated muscles were all normal (18). Normal glucose tolerance in transgenic mice 
overexpressing a kinase-dead AMPKα2 mutant (K45R mutation) in cardiac skeletal muscle 
(AMPKα2-KD) (19) argues against the hypothesis that muscular AMPK is sufficient by itself 
to deteriorate the glucose homeostasis (18). Another known important mechanism of insulin 
resistance in skeletal muscle is increased lipid availability or increased muscular uptake of 
free fatty acids (FFA). Surprisingly, intramuscular lipid content in AMPKα2-/- and control 
mice were comparable indicating no alteration in lipid oxidation ability in AMPKα2-/- mice. 
This conclusion is also supported by similar 24-hour respiratory quotient and energy 
expenditure in AMPKα2-/-, AMPKα1-/- and control mice (Table 2). Thus, lipid oxidation 
cannot be altered at the whole-body level by the deletion of either AMPKα2 or AMPKα1 
subunits. At this time, how can one explain that lack of AMPKα2 subunit can alter both 
insulin sensitivity and insulin secretion in vivo? It is now established that in vivo impaired 
insulin action and reduced insulin secretion observed in AMPKα2-/- mice are both linked to 
altered function of the autonomic nervous system in integrating peripheral metabolic signals. 
Indeed, increase in catecholamine release in AMPKα2-/- mice could explain development of 
insulin resistance and glucose intolerance in vivo (18). This suggested that the hypothalamic 
AMPKα2 contributes to the balance between the whole-body metabolic changes and the 
sympathetic tone which in turn regulates the peripheral metabolism. 
 
 
Role of AMPK in hepatic metabolism 
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Hepatic metabolism plays a key role in the control of whole-body energy status since liver is 
the major site for storage and release of carbohydrates and for the synthesis of fatty acid. In 
the liver, AMPK coordinates the changes in the activity of enzymes of the lipid metabolism 
and, so, regulates the partitioning of fatty acids between oxidative and biosynthetic pathways. 
In the cholesterol synthesis pathway, AMPK phosphorylates and inhibits hydroxy-3-
methylglutaryl-coenzyme A (HMG-CoA) reductase blocking the conversion of HMG-CoA to 
mevalonate. In total and liver-specific AMPKα2-/- mice, plasma levels for total and HDL 
cholesterol are not statistically different compared to controls but have a tendency to be 
higher. This suggested that remaining α1 subunit activity in AMPKα2-/- mice is sufficient to 
control hepatic cholesterol synthesis and that HMG-CoA reductase is probably a target for 
both AMPK catalytic subunits. Acetyl-CoA carboxylase (ACC) is an important rate-
controlling enzyme for the synthesis of malonyl-CoA, which is both a critical precursor for 
biosynthesis of fatty acids and a potent inhibitor of mitochondrial fatty acid oxidation. 
Phosphorylation and inhibition of ACC by AMPK leads to a fall in malonyl-CoA content and 
a subsequent decrease in triglyceride synthesis concomitantly with an increase in β-oxidation. 
This was first evidenced by the decrease in plasma triglyceride levels during AICAR infusion 
in lean and obese rodents. These results are consistent with ex vivo findings demonstrating the 
AICAR-induced inhibition of mitochondrial glycerol-3-phosphate acyltransferase (GPAT) 
activity and subsequent inhibition of triacylglycerol synthesis (20). In addition, 
overexpression of AMPKα2 in the liver decreases plasma triglyceride levels and increases 
plasma ketone bodies levels, a surrogate marker for hepatic β-oxidation (21). Conversely, 
liver-specific AMPKα2 deletion leads to increased plasma triglyceride levels and reduction in 
plasma ketone bodies levels. This emphasizes the critical role for AMPKα2 subunit in the 
control of the balance between hepatic lipogenesis and β-oxidation. 
As reported recently, AMPK has been also involved in the control of mitochondrial 
biogenesis in the liver. First evidences were brought by treatment with resveratrol, a 
polyphenol constituent of red wine, which increases mitochondrial number in liver in 
association with AMPK activation (22). Second, AMPKα1α2LS-/- mice have reduced 
mitochondrial biogenesis as suggested by decreased transcript and protein expression of key 
mitochondrial constituents such as peroxisome proliferator-activated receptor-γ coactivator-1 
α (PGC-1α), cytochrome c oxidase I (COX I), COX IV and cytochrome c genes (23). 
Interestingly, both mitochondrial respiration and basal level of ATP were significantly lower 
in hepatocytes isolated from AMPKα1α2LS-/- mice compared with control mice (24). This 
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result emphasizes the importance of AMPK in the regulation of cellular energy homeostasis 
via the control of adaptive mitochondrial function. Thus, diminished AMPK activity may be 
an important contributing factor in the reduced mitochondrial function and dysregulated 
intracellular lipid metabolism associated with hepatic insulin resistance. 
Recent results from various animal models confirm the physiological importance of hepatic 
AMPK for whole-body glucose homeostasis. It has been first shown that systemic infusion of 
AICAR in normal and insulin-resistant obese rats leads to the inhibition of hepatic glucose 
production (HGP) (25). Short-term activation of AMPK specifically in the liver by 
adenovirus-mediated expression of a constitutively active form of AMPKα2 (AMPKα2-CA) 
is sufficient for controlling hyperglycemia in murine models of diabetes (21). Liver-specific 
deletion of AMPKα2 results in mild hyperglycemia and glucose intolerance due to increased 
fasted HGP (26). These data indicate that remaining hepatic AMPKα1 is not sufficient to 
control HGP in the post-absorptive state. Thus, these results demonstrate that hepatic 
AMPKα2 is essential to control HGP and maintain fasting blood glucose levels in the 
physiological range. In addition, it has been also recently demonstrated that in the absence of 
hepatic LKB1, AMPK was almost completely inactive and fasting blood glucose levels were 
highly increased (27). In liver-specific LKB1-/- mice, the antidiabetic drug metformin no 
longer reduced blood glucose levels providing the apparent possibility that LKB1-mediated 
activation of AMPK in the liver might be required to lower blood glucose levels (27). 
Knowing the fact that LKB1 regulates thirteen different downstream protein kinases including 
AMPK, these data raised the question whether glucose-lowering function of LKB1 is 
mediated by one or several of these AMPK-related kinases rather than AMPK itself. In order 
to evaluate the respective contribution of AMPK in liver and skeletal muscle for the control of 
blood glucose levels, mice lacking both α1 and α2 catalytic subunits in the liver 
(AMPKα1α2LS-/-) were submitted to hypoglycemic effect of AICAR. AMPKα1α2LS-/- mice 
showed severe AICAR resistance (Figure 1). Since AICAR effect in skeletal muscle is similar 
in both AMPKα1α2LS-/- and control mice, the resistance to the hypoglycemic effect of 
AICAR observed in AMPKα1α2LS-/- mice is due to the lack of hepatic AMPK. The 
difference between the glycemic excursion in AMPKα1α2LS-/- and control mice corresponds 
to the contribution of hepatic AMPK for the inhibition of HGP. Thus, the participation of the 
liver in AICAR hypoglycemic action represents about 40% (Figure 1), indicating that hepatic 
AMPK has a crucial role in the control of blood glucose levels. Furthermore, the potent 
effects of circulating adipocyte-derived hormones on whole-body glucose metabolism 
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recently highlighted the involvement of AMPK in the control of glucose output by the liver. 
Indeed, a physiological link has been established between increased resistin plasma levels (as 
observed in insulin resistant rodent models) and increased liver glucose output through the 
inhibition of AMPK activity (28). Moreover, it has been recently demonstrated that 
hypoglycemic effect of adiponectin appears to be mediated by hepatic AMPK activation (29). 
This was corroborated with the incapacity of adiponectin to regulate HGP in the absence of 
the AMPKα2 subunit in the liver (26). 
Although the action of AMPK in systemic energy balanced is achieved by rapid and direct 
phosphorylation of metabolic enzymes, long-term effects has also been clearly demonstrated 
on glycolytic and lipogenic gene expression in the liver by adenovirus-mediated gene transfer 
of AMPKα2-CA (21). Obese ob/ob mice provide an animal model of non-insulin dependent 
diabetes mellitus, exhibiting hyperglycemia, hyperinsulinemia and obesity. ob/ob mice 
maintains a high level of hepatic lipogenesis linked with increased expression of lipogenic 
and glycolytic genes. Overexpression of AMPKα2-CA in the liver of ob/ob mice allows the 
normalization of expression pattern of these genes (Figure 2). Of note, AMPK activation 
reduces expression of sterol regulatory element–binding protein-1c (SREBP1c) and 
carbohydrate response element–binding protein (ChREBP), transcription factors playing a key 
role in the transcriptional regulation of lipogenic and glycolytic genes by insulin and 
glucose, respectively. Polyunsaturated fatty acids (PUFAs) are also known to exert repression 
on glycolytic and lipogenic gene and raised the question about a role of AMPK in mediating 
the effect of PUFAs on gene transcription. The ability of PUFAs to directly modulate AMPK 
activity remains controversial and to address the role of AMPK in the inhibitory effect of 
PUFAs in liver, a series of experiments have been performed in AMPKα1-/-, AMPKα2-/- 
and AMPKα1α2LS-/- mice. Under both in vivo and in vitro experimental conditions, no 
change in AMPK activation was observed in the presence of PUFAs (30). Indeed, results 
obtained in AMPK KO mice clearly show that AMPK is not involved in the control of 
ChREBP nuclear translocation and in mediating the negative effect of PUFAs on both 
glycolytic and lipogenic gene expression (9, 30). Together, these data demonstrate that 
PUFAs inhibit ChREBP nuclear translocation and repress glycolytic/lipogenic gene 
expression by an AMPK-independent mechanism. AMPK has been also implicated in the 
transcriptional regulation of drug-metabolizing enzyme cytochrome P450 (CYP) gene family. 
The CYP genes plays a crucial role in the transformation of xenobiotics by the liver and their 
expression is strongly induced in response to phenobarbital (PB) administration. In 
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AMPKα1α2LS-/- mice, PB failed to induce the expression of CYP genes indicating that 
AMPK play a crucial role in the regulation of drug metabolism (31). 
 
 
Role of AMPK in adipose tissue 
Adipocytes have both metabolic and endocrine functions. Energy storage under food 
availability is a determinant of survival in period of increased energy expenditure or fasting. 
Triacylglycerol (TAG) exists as the most efficient macromolecule for this storage. When 
needed, triglycerides are hydrolyzed (lipolysis) into fatty acids and glycerol which are 
exported back into the blood. It has been reported that activation of AMPK in adipocytes 
results in the inhibition of both lipolysis and lipogenesis by regulating directly the enzymes 
engaged in lipid metabolism (32), as well as by downregulating PPARγ expression (33). 
Another consequence of AMPK activation in adipose tissue is an increase in fatty acid 
oxidation. This has been demonstrated when the uncoupling mitochondrial protein UCP-1 is 
overexpressed in adipocytes. In this case, the resulting activation of AMPK and inactivation 
of ACC (34) leads to a fall in malonyl-CoA content and a subsequent increase in 
mitochondrial fatty oxidation via the allosteric regulation of carnitine palmitoyltransferase-1 
(CPT-1) which catalyzes the entry of long chain fatty acyl-CoA into mitochondria. In 
addition, UCP-1 overexpression is concomitant to mitochondrial biogenesis and, so, promotes 
fatty acid oxidation process (35). A crucial function of adipocytes is to release stored 
triglycerides when needed. AMPK activation in adipocytes, using AICAR or overexpression 
of a constitutively active form of AMPK has been shown to inhibit β-adrenergic-induced 
lipolysis (32, 36, 37). This correlates with decreased plasma triglycerides, fatty acid 
concentration and glycerol turnover in both lean and obese rats infused with AICAR (25).This 
is explained by both HSL phosphorylation on Ser565 in adipocytes and reduction of 
isoproterenol-induced HSL translocation to the lipid droplet (37). Whether perilipin is a target 
of AMPK is presently unknown. Interestingly, in mice lacking the predominant AMPKα1 
isoform, the size of adipocytes is reduced and both basal and isoproterenol-induced lipolysis is 
higher than that of control adipocytes (37). Even if AMPKα1 subunit is predominant in 
adipocytes, deletion of AMPKα2 subunit is also followed by modifications in adipose tissue. 
Indeed, AMPKα2-/- mice submitted to high fat diet exhibited increased body weight and fat 
mass (38). The increase in adipose tissue mass was due to the enlargement of the pre-existing 
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adipocytes with increased lipid accumulation. This study demonstrates that lack of AMPKα2 
subunit may be a factor contributing to the development of obesity. 
 
 
Role of AMPK in skeletal muscle 
In skeletal muscle, AMPK is activated in response to both endurance exercise (e.g. in rat 
muscle during treadmill running and in human muscle during cycle exercise) (39, 40) and ex 
vivo contraction (electrical stimulation) (41). AMPK is therefore believed to be an important 
signaling molecule in regulating muscle metabolism during exercise (42). Indeed, a decrease 
of the voluntary activity of AMPKα2-KD mice, named “lazy mice” for this reason, has been 
reported (19). Moreover, muscle-specific transgenic mice expressing an inactive 
AMPKα2D157A mutant (AMPKα2i) have significantly lower exercise tolerance (43) 
suggesting a direct role of AMPK in the adaptation to exercise. Surprisingly, AMPKα2-/- 
mice ran the same distance per day at the same maximal speed as their littermate controls over 
8 weeks of running wheels training (Figure 3A and B). The sole effect of AMPKα2 deletion, 
if any, was a decrease in the stride length for AMPKα2-/- mice, which was compensated by 
an increase in number of runs compared to the controls (Figure 3C and D). Thus, the lack of 
AMPKα2 would not change the mice ability to perform physical exercise and training. 
Accordingly, no alteration in exercise-induced activation of metabolic genes in skeletal 
muscle has been detected in control and AMPKα2-/- mice during voluntary wheel activity 
(44) or forced activity on treadmill (45). In AMPKα2-KD and AMPKα2i mice, it has also 
been reported similar results with a normal increase of glucose transporter GLUT4 mRNA 
after treadmill running (46). However, in AMPKα2i mice, exercise training did not 
upregulate hexokinase II gene expression (47) suggesting increased capacities for glucose 
phosphorylation as an adaptation to endurance training. This discrepancy could be due to 
differences in the expression of the remaining AMPKα1 subunit in these various genetic 
animal models. AMPKα1 subunit is still present in AMPKα2-/- and AMPKα1 activity can be 
detected in AMPKα2-KD mice and may sustain alone the coordination of muscle metabolism 
and adaptation to exercise. It has been reported that AMPKα1 activity is higher in AMPKα2-
/- muscle as compared to control muscles, suggesting a compensatory effect (44). 
Nevertheless, recent studies using transgenic mice over-expressing an active γ1R70Q mutant 
in skeletal muscle supported the critical role of AMPK in training adaptation. Indeed, 
chronically increased muscle AMPK activity significantly rised the relative proportion of type 
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IIa/x fibers and the activity of mitochondrial markers in sedentary transgenic animals 
compared to their sedentary controls, without any further increase with exercise training (47). 
Moreover, the proportion of type IIa/x fibers in trained AMPKα2i mice was significantly 
lower than in their trained controls but no difference for mitochondrial markers was observed 
in response to exercise training (47). 
While it has been known for more than 75 years that physical activity is associated with 
increased mitochondrial content in muscle, the molecular mechanisms for this adaptive 
process has only recently been partly elucidated. The first major regulator of mitochondrial 
biogenesis discovered was PGC-1α which induces mitochondrial biogenesis by activating the 
transcription of nuclear respiratory factors 1 and 2 and of mitochondrial transcription factor A 
whose responsive elements have been found in the gene promoters of a number of 
mitochondrial proteins. Interestingly, activation of AMPK with AICAR (48) or with β-
guanidinopropionic acid (β-GPA) (49), a creatine analogue that is known to induce muscle 
adaptations similar to those induced by exercise training, led to activation of the 
mitochondrial transcription cascade. Furthermore, activation of AMPK by physical exercise 
or by over-expressing an active γ1R70Q mutant in muscle has been associated with an 
increase in PGC-1α and mitochondrial markers gene expression, making a direct link between 
AMPK and mitochondrial biogenesis (50, 51). A recent report revealed that PGC-1α is 
required for AMPK-dependent activation of gene expression, including PGC-1α itself, 
GLUT4 and mitochondrial genes (10). In addition, AMPK directly phosphorylates PGC-1α 
suggesting that posttranslational modifications of PGC-1α may participate in the regulatory 
functions of AMPK in skeletal muscle, integrating environmental changes into the 
corresponding metabolic adjustments (10). Accordingly, a decrease in the expression of PGC-
1α and several mitochondrial markers was observed in resting muscles from AMPKα2-/- 
mice (44, 45) and AMPKα2i transgenic mice (51). Finally, chronic muscle energy deprivation 
induced by β-GPA treatment had no effect on mitochondrial content and PGC-1α expression 
in AMPKα2-KD (52) suggesting that AMPK might be a regulator involved in the initiation of 
mitochondrial biogenesis. 
Reductions in AMPK-stimulated activity have recently been implicated in the reduced 
mitochondrial function and dysregulated intracellular lipid metabolism associated with aging-
induced insulin resistance and type 2 diabetes (53). Oxidative capacity of fast/glycolytic 
(plantaris) and slow/oxidative (soleus) skeletal muscles from AMPKα2-/- mice were directly 
measured in permeabilized fibers from sedentary animals to evaluate the role of AMPK in 
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mitochondrial function. No modification in muscle oxidative capacity of soleus or plantaris 
muscles was observed in AMPKα2-/- mice (Table 3). Both basal and maximal respiration 
were similar in control and AMPKα2-/- soleus and plantaris muscles. Coupling between 
respiratory chain and phosphorylation was also intact in the absence of AMPKα2 in skeletal 
muscle (Table 3). Following endurance training for 8 weeks, an increase of mitochondrial 
respiration with the addition of different substrates (which became significant with the last 
addition of substrates, namely pyruvate and glutamate), was observed in the soleus muscle of 
trained control mice (Figure 4A, left panel) but not in trained AMPKα2-/- soleus muscle 
(Figure 4A, right panel). In the case of plantaris muscle, no effect of training was observed on 
respiration rates either for control (Figure 4B, left panel) or AMPKα2-/- (Figure 4B, right 
panel) mice. These results indicate that AMPKα2 could participate in the adaptation to 
endurance training in oxidative muscle by improving the mitochondrial respiration under 
different substrates. 
Endurance training is known to induce a partial fast-to-slow muscle phenotype transformation 
and mitochondrial biogenesis but no growth. In contrast, resistance training mainly stimulates 
muscle protein synthesis resulting in hypertrophy. For muscle growth to occur, the rate of 
protein synthesis must exceed that of protein breakdown. Since protein synthesis can account 
for up to 30-50% of the cellular energy expenditure, a reduction in protein synthesis seems an 
efficient mechanism to save energy. One critical signaling pathway controlling protein 
synthesis during skeletal muscle growth involves the mammalian target of rapamycin 
(mTOR) kinase. mTOR has emerged as an essential factor for growth and development 
activated in skeletal muscle by a variety of anabolic signals like resistance exercise. The use 
of mTOR inhibitor rapamycin has demonstrated that mTOR is required for hypertrophy. On 
the contrary, AMPK activity is thought to inhibit protein synthesis, which is important for 
skeletal muscle hypertrophy, and may therefore modulate skeletal muscle mass and 
hypertrophy (54). Increased AMPK phosphorylation in fast-twitch plantaris muscle has been 
associated with an impaired hypertrophic capacity (55, 56). In parallel, with the mTOR 
pathway, studies suggest that AMPK reduces both the initiation and the elongation of 
ribosomal peptide synthesis (57). In rat skeletal muscle, activation of AMPK by AICAR is 
shown to associate with a reduced protein synthesis (54). The effect of AMPK on protein 
synthesis is likely to be due, in part, to AMPK-induced inhibition of the mTOR/ ribosomal 
protein S6 kinase (S6K) signaling pathway (54, 58-60). Indeed, this pathway contains 
multiple potential sites for regulatory integration with AMPK (54, 61). For example, AMPK 
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phosphorylates and activates the GAP protein named tuberous sclerosis complex 2 (TSC2). 
Once activated, TSC2 is able to inactivate its G-protein Rheb thereby blocking activation of 
mTOR (9, 61). It has been also shown that AMPK could directly phosphorylate and inactivate 
mTOR (62). In parallel, with the mTOR pathway, AMPK reduces protein synthesis by a 
specific phosphorylation (Ser398) on the eEF-2 kinase (59), which is a key component in 
protein synthesis as it promotes peptide elongation. In addition to the AMPK-induced mTOR 
regulation, it has been recently shown that, on the other way, the suppression of S6K1 activity 
simultaneously promotes AMPK signaling (63). 
Numbers of studies have investigated whether AMPK is an important signaling molecule in 
the control of skeletal muscle glucose transport. Muscles from AMPKα2-/-, AMPKγ3-/-, 
AMPKα2-KD and AMPKα2i mice completely abolished ex vivo AICAR- or hypoxia-
stimulated glucose uptake (17, 19, 64, 65). Based on these observations, AMPK has been 
proposed to be a key player in initiating signaling to contraction-stimulated glucose uptake. 
Nevertheless, it has been difficult to verify this hypothesis with genetic approaches. In 
AMPKα2-/-, AMPKγ3-/-, AMPKα2-KD and AMPKα2i mice ex vivo contraction-stimulated 
glucose uptake is normal (17, 65) or only moderately reduced (64, 66). Recent observations 
using aforementioned genetic animal models suggested that Akt substrate of 160 kDa 
(AS160), a key protein in the regulation of insulin-dependent GLUT4 trafficking and glucose 
uptake, may represent a point of convergence between AMPK and insulin-signaling pathways 
for the control of glucose uptake. AICAR-induced AS160 phosphorylation was completely 
prevented in AMPKα2-/-, AMPKγ3-/- and AMPKα2-KD mice (67, 68). However, the 
situation was different in response to contraction as AS160 phosphorylation was impaired in 
AMPKα2-/- and AMPKα2-KD mice but not in AMPKγ3-/- mice (68). These results 
highlighted the importance of isoform composition of AMPK complexes in the regulation of 
exercise-induced phosphorylation of AS160 with α2β2γ1 playing probably a central role (6). 
Interestingly, muscle-specific LKB1 KO mice which lack the ability of AMPKα2 to be 
phosphorylated and activated displayed an impaired capacity to stimulate both contraction 
and AICAR-stimulated glucose uptake (7). However, these results do not directly link AMPK 
activity and glucose transport, as LKB1 phosphorylates and activates several other kinases 
which could contribute to glucose transport during contraction. Thus, taken together, these 
data indicate that AMPK can regulate glucose uptake in resting muscle and that AMPK plays, 
at least partially, a role in the contraction-stimulated glucose uptake. 
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AMPK is also pivotal in the regulation of skeletal muscle fatty acid metabolism. AMPK 
activation with AICAR, leptin or adiponectin induces increasing rates of fatty acid oxidation 
via phosphorylation and inactivation of ACC (29, 69, 70). Interestingly, leptin was found to 
selectively activates and phosphorylates AMPKα2 in skeletal muscle via direct and indirect 
mechanisms; the latter involving the hypothalamic-sympathetic nervous system and α 
adrenergic receptors in muscle (70). During muscle contraction, the activation of AMPK 
inhibits ACC resulting in long-chain fatty acids β-oxidation. First evidence for the role of 
AMPK in the regulation of fatty acid oxidation in skeletal muscle has been obtained from 
mice overexpressing the activating γ3 R225Q mutation in muscle. These transgenic mice 
showed increased fatty acid oxidation when challenged with a fat-rich diet or after swimming 
exercise leading to reduced intramuscular accumulation of triglycerides (65, 71). Thus, the 
AMPKγ3 isoform plays a major role in modulating intramuscular fuel utilization toward fat 
oxidation during exercise. Nonetheless, recent studies demonstrated the importance of 
alternative pathways on upregulation of fatty acid oxidation in the absence of AMPK activity 
during muscle contraction (72, 73) and the additive effects of contraction and AICAR on fatty 
acid oxidation (74) suggesting parallel pathways for regulating fatty acid oxidation during 
muscle contraction. However, because oxidative metabolism is important during endurance 
exercise, changes in lipid metabolism in response to AMPK activation may also affect 
glycogen metabolism in skeletal muscle. The level of muscle glycogen is essential for muscle 
performance. Indeed, glycogen represents the main source of glucose for muscle ATP 
synthesis early during a bout of exercise. Glycogen synthase (GS) is believed to be the rate 
limiting enzyme in the glycogen synthesis. In mouse white skeletal muscle, AMPKα2 but not 
AMPKα1 is able to phosphorylate and inactivate GS in vivo in response to AICAR treatment 
(75), which is in agreement with the role of AMPK in the control cellular of energy balance. 
Recently, the role of AMPK in the regulation of muscle glycogen has been further 
investigated with AMPKγ3-/- and AMPKα2-KD mice and transgenic mice over-expressing 
AMPKγ mutants specifically in skeletal muscle (65, 76, 77). Over-expression of γ3R225Q 
and γ1R70Q mutant activates AMPK and increases muscle glycogen content accompanied by 
an higher exercise capacity (71, 77) but glycogen resynthesis after exercise is blunted in 
AMPKγ3-/- and AMPKα2-KD mice (19, 65). 
Although, pharmacological activation of AMPK in resting muscle has been demonstrated to 
act on muscle metabolism, the available data from current animal models do not allow to 
drive firm conclusions about the physiological role of AMPK during exercise and muscle 
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contraction. All the studies using AMPK animal models have brought a quantity of results 
which are, to some extent, difficult to connect, and even more are contradictory. This conflict 
could come from the difficulties to compare different genetic animal models. Indeed, 
expression of a dominant-negative form of AMPK is clearly not equal to the deletion of a 
particular AMPK subunit. Another reason may be the many additional signaling pathways 
that are activated during exercise which may have overlapping actions to AMPK. Clearly, 
more in vivo approaches using new animal models or specific inhibitor strategies are needed 
to comprehensively understand the role of AMPK in muscle metabolic adaptation during 
exercise training. 
 
 
Role of AMPK in the heart 
In comparison to hepatic and adipose tissue, the heart could be considered as a simplistic 
organ, which its function is to be a modest circulating pump. However, this cardiac pump has 
to continuously adapt its function and, so, its energy consumption to the oxygen demand and 
circulating substrates and hormones in the body. In normal conditions, the human heart 
produces and directly consumes 35kg of ATP each day. This energy comes from the 
oxidation of different substrates, including fatty acids and glucose (Figure 5A). This oxidation 
requiring a continuous flux of oxygen, any reduction of this flux, for example during an 
ischemic episode, will inevitably induce an energetic imbalance, an increase in AMP/ATP 
ratio and, so, AMPK activation (Figure 5B). It has been postulated that this resulting AMPK 
activation acts as an emergency signal to restore cell energy homeostasis (78-81). Indeed, it is 
assumed that AMPK promotes glycolysis, the sole energy providing pathway under anaerobic 
conditions, by a double mechanism (Figure 5B). First, it increases glucose uptake by 
stimulating the translocation of glucose transporter GLUT4 to the sarcolemmal membrane. 
Second, AMPK indirectly stimulates 6-phosphofructo-1-kinase (PFK-1) activity by 
phosphorylating and activating 6-phosphofructo-2-kinase, the enzyme that synthesizes 
fructose 2,6-bisphosphate, a potent PFK-1 stimulator. By participating in the stimulation of 
glycolysis and, so, in the ATP production, AMPK is considered to play a protective role 
during an ischemic episode. By contrast, it has been postulated that AMPK could play a 
deleterious role during early reperfusion. Indeed, during reperfusion, the still existing AMPK 
activation helps fatty acid oxidation to predominate over glucose oxidation by 
phosphorylating and inactivating ACC. This ACC inactivation decreases the concentration of 
malonyl-CoA and so increases fatty acid oxidation (Figure 5C). During the early phase of 
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reperfusion, this resulting stimulation of fatty acid oxidation occurs in parallel to the still 
present glycolytic stimulation, inducing a deleterious uncoupling of glucose oxidation and 
glycolysis (78). Transgenic animal models have been extensively used to answer to the 
question if AMPK is a friend or a foe for the heart during an ischemia/reperfusion episode. 
The study of AMPKα2-/- mouse heart (82), the AMPKα2 isoform being predominant in the 
heart, and of AMPKα2-KD mice where a kinase-dead AMPKα2 isoform (K45R mutation) is 
expressed in the heart (19, 83), confirmed the major role of AMPK in the regulation of 
cardiac metabolism. Indeed, in the absence of the AMPKα2 isoform, ACC phosphorylation in 
both normoxic and ischemic conditions was clearly decreased (82). This correlates to the 
absence of the stimulation of fatty acid oxidation during reperfusion in AMPKα2-KD mouse 
hearts (83). Similarly, in both models (83, 84) as well as in heart AMPKα2i model (D157A 
mutation) (85), basal and/or ischemia-stimulated glucose uptake were downregulated, 
whereas the stimulation by ischemia of glycolysis, measured by lactate production, was 
decreased (82, 83). The decrease in glycolytic stimulation during ischemia induced a major 
energetic imbalance. Indeed, at the end of the ischemic episode, AMP/ATP ratio reached 
values 10-times higher in AMPKα2-/- mouse hearts in comparison to that of wild-type animal 
(82). In term of cardiac function, this robust energetic imbalance is accompanied by a more 
rapid and severe ischemic contracture of the AMPKα2-/- mouse hearts (82, 84). Similar 
results were found in AMPKα2-KD model where the left ventricular developed pressure is 
clearly lower than in wild-type hearts during ischemia (83). Even if the link between 
modifications of metabolic regulation and heart function is difficult to establish, these results, 
taken together, showed that the decrease of AMPK activation is detrimental for the heart 
during ischemia.  
However, the effect of AMPK activity deletion on the heart function during reperfusion is less 
clear. Indeed, AMPKα2-KD hearts demonstrated impaired recovery of left ventricular 
function accompanied by an increase in myocardial injury and apoptosis (83). By contrast, in 
AMPKα2-/- hearts, despite the apparent worse metabolic adaptation during ischemia, the 
absence of AMPKα2 isoform does not exacerbate impairment of the recovery of post-
ischemic contractile function in the absence of fatty acids (82, 84) and has transient and 
limited effect in the presence of fatty acids (84). 
Another important role of AMPK in the heart is its contribution in the regulation of glycogen 
metabolism, even if the pathways controlled by AMPK and involved in the regulation of 
glycogen synthesis and breakdown remain to be fully elucidated (78, 86). Different mutations 
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of the AMPKγ subunit have been shown to induce an increase in glycogen storage and 
cardiomyopathy characterized by a ventricular pre-excitation, named Wolff-Parkinson-white 
(WPW) syndrome. Different transgenic models overexpressing these mutations in the heart 
have been extensively studied (78, 86). These models are all characterized, amongst others, 
by an increase in glycogen content. By contrast, the action of these mutations on AMPK 
activity and AMPK sensitivity to AMP seemed to be partially different, if not opposite. If it is 
rather difficult to conciliate, at first sight, a same increase in glycogen content but different 
AMPK activity, a model of AMPK/glycogen relationship has been proposed (86). Firstly, 
these mutations induce inappropriate activation of AMPK under basal conditions. This 
abnormal AMPK activation leads to a concomitant increase in both glucose uptake and fatty-
acid oxidation, inducing, via the Randle effect, an inhibition of glucose oxidation and, so, the 
storage of the exceeding glucose into glycogen. This increase in glycogen content, 
subsequently, inhibits AMPK, reaching a new steady state. This putative model is in 
agreement with the results obtained in different genetic models, with altered AMPK activity. 
In AMPKα2-KD (83) and AMPKα2-/- hearts (82, 84), loss of AMPK activity is correlated to 
the reduction of glycogen content. However, it should be mentioned that the relationship 
between glycogen storage and AMPK is not simply related to its activity/activation. Indeed, 
LKB1-/- hearts (8) possess an AMPK activity profile similar to that of AMPKα2-/- hearts 
(82). That is a complete inactivation of the AMPKα2 isoform without (for AMPKα2-/-) or 
with only a little decrease (for LKB1-/-) in AMPKα1 activity or ischemia-induced activation. 
Under the same ischemic condition, LKB1-/- heart was characterized by a 10-fold higher 
energetic resistance measured by the increase in AMP/ATP ratio (AMP/ATP ratio reached 
after 10 min of ischemia: 0.33 and 3.5 for LKB1-/- and AMPKα2-/-, respectively) (8, 82). 
This is linked to superior glycolytic stimulation measured by lactate accumulation (Figure 6) 
and could be associated to the higher glycogen content under normoxic condition (Figure 6). 
So, similar AMPK activity coexists with different glycogen storage. One of the main 
differences between LKB1-/- and AMPKα2-/- animals does not reside in the activity but in 
the physical presence of the protein. Indeed, the expression of the different AMPK subunits, 
including AMPKα2 is not modified in LKB1-/- mouse hearts, whereas AMPKα2 is, 
obviously, not expressed in AMPKα2-/- mice. Interestingly, the modification of the amount 
of the AMPKα2 subunit is accompanied by the decrease in AMPKβ subunit (82). Knowing 
the fact that the AMPKβ subunit possesses a glycogen binding domain, we can postulate that 
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glycogen storage is also, at least partially, regulated via its direct interaction with the AMPK 
heterotrimer, independently of its intrinsic activity. 
As already explained, mutations of the AMPKγ subunit have been shown to induce 
cardiomyopathy characterized by a ventricular pre-excitation WPW syndrome. The study of 
different mouse genetic models of AMPKγ2 missense mutation, including transgenic R302Q 
(87), N488I (88, 89), R531G (90) and T400N (91), concluded that the WPW cardiomyopathy 
resulted, at least partially, from physical disruption of conduction cells by glycogen 
engorgement (86). In addition, other mechanisms have been proposed to act in parallel, 
including AMPK-induced phosphorylation of ion channels. Similarly to these AMPKγ 
mutations, the cardiac-specific dominant-negative TAK1 mice were characterized by 
electrophysiological and biochemical properties similar to WPW syndrome and impaired 
AMPK activation (92). The author of this study concluded that TAK1 plays a pivotal role in 
the LKB1/AMPK signaling. 
Finally, the study of genetic models of AMPK revealed new roles for this enzyme. Indeed, 
using AMPKα2-KD, it has been recently reported that AMPK plays an important role in p38 
MAPK activation during ischemia by promoting p38 MAPK autophosphorylation through 
interaction with the protein TAB1 (93). On the same way, in the heart AMPKα2i model (85), 
it has been shown that AMPK mediates cardiac preconditioning by regulating the activity and 
recruitment of sarcolemmal K(ATP) channels (94). On the other hand, the study of AMPKα2-
/- mouse heart revealed that AMPKα2 participates in the regulation of cardiac muscle 
oxidative capacity (95). The absence of AMPKα2 induced the decrease of the maximal 
oxidative capacity and an impairment of the complex I of the respiratory chain. This was 
associated to a decrease in mitochondrial cardiolipin content that could be explained by the 
downregulation of mRNA of enzymes involved in cardiolipin synthesis and remodeling. 
 
 
Role of AMPK in vascular reactivity 
AMPK is expressed both in endothelial and in smooth muscle cells. Previous studies have 
established that the predominant isoform expressed in vascular endothelial cells is α1 (96, 
97). Both α1 and α2 catalytic subunits are expressed in arterial smooth muscle cells, although 
their relative proportion differs between different arteries (12, 98). Vasodilatation is a vital 
mechanism of systemic blood flow regulation that occurs during periods of increased energy 
demand. As a metabolic sensor, vascular AMPK could be involved in the metabolic 
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regulation of blood flow. Hypoxia increases the AMP/ATP ratio in pulmonary artery smooth 
muscle cells and induces a two-fold increase in AMPK activity (12). Metabolic challenge also 
rapidly and reversibly activates AMPKα1 in porcine carotid arteries (98), suggesting that 
AMPK activation may participate in the regulation of blood pressure. Indeed, AICAR 
treatment decreased blood pressure in rats displaying features of the insulin resistance 
syndrome (99). A target of AMPK is endothelial nitric oxide synthase (eNOS), an important 
modulator of angiogenesis and vascular tone. It has been clearly established that AMPK may 
associate with, and phosphorylate eNOS in cardiomyocytes and endothelial cells, thus 
increasing eNOS activity and NO production (96, 100). Activation of AMPK with AICAR 
stimulates NO synthesis in human aortic endothelial cells (101). 
Thus, AMPK could trigger vasodilatation and participate in blood flow regulation. Indeed, 
pharmacological activation of AMPK by AICAR induces relaxation of mouse aorta (102). 
This AICAR-induced vasorelaxation is not inhibited by the addition of adenosine receptor 
antagonists. Moreover, when aortic rings are freed of endothelium or pretreated with L-
NMMA to inhibit nitric oxide synthase activity, AICAR still induces aortic ring relaxation, 
suggesting a direct effect of AICAR on smooth muscle cells. Finally, AICAR-induced 
relaxation of aortic rings is completely abolished in AMPKα1-/- but not AMPKα2-/- mice 
(102). Therefore, activation of AMPKα1 but not AMPKα2 is able to induce aortic relaxation 
in mice, in an endothelium and eNOS-independent manner. AMPK activation may be an 
additional mechanism by which hypoxia or metabolic challenge can induce vasorelaxation of 
large vessels, thereby increasing oxygen availability in peripheral tissues. AMPK thus appears 
as a new player in the complex signaling pathways that regulate vascular tone. 
 
 
Role of AMPK in the hypothalamus 
The central nervous system, in particular the hypothalamus, plays an essential role in the regulation of 
feeding behavior and energy expenditure by integrating information from the periphery through 
nutrients, hormones and afferent neural inputs (103). The emerging role of hypothalamic AMPK in 
these pathways involved in whole body energy homeostasis has received considerable attention 
during the last years (104-106), highlighting a more central and integrated function for AMPK than 
the one primarily recognized as cellular energy sensor. The most striking proof of concept for AMPK 
involvement in appetite regulation came from experiments showing that expression of a constitutively 
active or a dominant negative form of AMPK in the hypothalamus induced reciprocal modifications 
of neuropeptides expression, food intake and body weight in mice (107). Thus, elevated hypothalamic 
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AMPK activity led to stimulation of food intake whereas its reduction was associated with 
hypophagia. In agreement with this genetic approach, it has been shown that acute intra-
cerebroventricular (icv) administration of pharmacological AMPK activator (AICAR) or inhibitor 
(compound C) increased or decreased food intake, respectively (108, 109). Furthermore, antagonistic 
effects on food intake were also observed after modulation of intra-hypothalamic ATP levels by icv 
injection of 2-deoxyglucose (orexigen, (110)) or the fatty acid synthase inhibitor C75 (anorexigen, 
(111)). Interestingly, a number of studies demonstrated that hypothalamic AMPK is also regulated 
under physiological conditions, its activation during starvation and inactivation upon refeeding being 
associated with nutritional changes in circulating hormones and nutrients (107, 111). Thus, it has been 
shown that hormones known to affect food intake could exert part of their effects through modulation 
of hypothalamic AMPK activity. The adipocytokine leptin and insulin, which exert anorexigenic 
effects, were reported to inhibit AMPK in both arcuate (ARC) and paraventricular hypothalamic 
nucleus by a mechanism that presumably involved the melanocortin 4 receptors (107). In other hand, 
the gut hormone ghrelin induced hypothalamic AMPK activation and stimulation of food intake (108, 
112). Furthermore, it has been very recently demonstrated that trimeric and hexameric forms of 
adiponectin were able to cross the blood brain barrier and to concomitantly increase AMPK activity in 
ARC nucleus and food intake in mice (113). In addition, adiponectin also reduced energy expenditure 
and remarkably reversed the leptin-induced suppression of hypothalamic AMPK activity and its 
subsequent inhibitory effect on food intake (113). All these effects required the presence of the 
adiponectin receptor adipoR1 (113). Finally, icv administration of resistin promoted short-term satiety 
in rats (114), although its inhibitory effect on AMPK reported in various tissues (115, 116) remains to 
be specifically addressed in the hypothalamus. In addition to these hormonal signals, nutrients may 
also be involved in the AMPK-mediated regulation of food intake. While opposite effects of glucose 
modulation on feeding behavior are known for decade, it has been recently shown that the hypophagia 
following icv injection of glucose could be mediated by suppression of AMPK activity in multiple 
hypothalamic areas (107, 109). Thus, AMPK is physiologically inhibited by elevated glucose level 
associated with refeeding and activated by a reduction of glucose availability during prolonged 
fasting. 
The mammalian target of rapamycin (mTOR) has been recently implicated in the hypothalamic 
control of food intake. However, conversely to AMPK, mTOR is activated by leptin, glucose and 
amino acids, leading to inhibition of food intake (117). Interestingly, since activation of AMPK 
suppresses mTOR activity, this strongly suggests that both kinases may have overlapping and 
reciprocal functions in the control of feeding behavior (117). The AMPK-mediated regulation of food 
intake involves complex modifications of orexigenic and anorexigenic neuropeptides expression, 
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notably in the ARC nucleus of the hypothalamus, a region containing both neuropeptides Y 
(NPY)/agouti-related protein (AgRP) and pro-opiomelanocortin (POMC)/cocaine- and amphetamin-
regulated transcript (CART) neurons. Indeed, inhibition of hypothalamic AMPK was reported to 
suppress neuronal NPY/AgRP signaling (107), this being eventually mediated by a cAMP response 
element-binding protein (CREB)-dependent mechanism (111), whereas elevated AMPK activity was 
associated with increased fasting-induced NPY and AgRP expression (107, 110). However, the 
underlying mechanism(s) connecting modulation of hypothalamic AMPK activity to expression of 
these neuropeptides remain unknown to date. It has been suggested that modulation of malonyl-CoA 
and/or long chain fatty acyl-CoA (LCFA-CoA) concentrations in the hypothalamus could act as 
potent regulators of food intake (118, 119). Accordingly, AMPK activation during starvation, which 
leads to phosphorylation and inactivation of ACC, would decrease hypothalamic malonyl-CoA and/or 
LCFA-CoA content, favor fatty acid oxidation and stimulate feeding (Figure 7). Since AMPK has 
been shown to phosphorylate and activate malonyl-CoA decarboxylase (MCD) (120), this could also 
participate to the reduction of malonyl-CoA level by increasing its degradation. In support to this 
mechanism, CPT1 inhibition (121) and adenovirus-mediated expression of MCD in the hypothalamus 
(122) have been associated with opposite changes in malonyl-CoA levels and neuropeptides 
expression, resulting in suppression or stimulation of food intake, respectively. Although recent 
evidence suggests that the brain-specific CPT1 isoform (CPT1c) may be one of the hypothalamic 
malonyl-CoA target that relays AMPK signaling to orexigenic and anorexigenic neurons (123), 
further studies will be needed to address this specific issue. In addition, the signal resulting from 
hypothalamic lipid sensing could come from LCFA itself since it has been reported that icv 
administration of fatty acids or manipulation of hypothalamic lipid metabolism also reduced food 
intake (121). 
Taken together, there is a growing body of evidence suggesting that hypothalamic AMPK 
plays a key role in appetite regulation by integrating nutrient- and hormonal-derived signals. 
However, it is striking that neither the AMPKα1 nor the AMPKα2 knockout mice exhibited 
apparent changes in body weight and mean daily food intake ((17, 18) and Table 2). While 
upregulation of the remaining AMPK isoforms should not be excluded, as previously reported 
in other tissues (18), it should be noted that these phenotype were observed on animals fed a 
normal chow diet ad libitum and may eventually differ in response to other diets (e.g. high 
fat). In addition, it would also be interesting to measure food intake during the first hours 
following refeeding in mice submitted to a prolonged fasting period to see if the starvation-
induced activation of AMPK in the hypothalamus is involved in the initiation of food intake. 
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Finally, the forthcoming generation of mice expressing neuron-specific deletion of α1 and α2 
isoforms of the AMPK catalytic subunits in specific regions of the hypothalamus would 
probably constitute a very helpful model to further study the involvement of AMPK in 
feeding behavior and energy expenditure. Thus, very recent results showed that newly 
engineered mice lacking AMPKα2 in POMC neurons unexpectedly developed obesity due to 
reduction of energy expenditure and dysregulation of food intake (124). In other hand, deletion 
of AMPKα2 in AgRP neurons led to divergent physiological effect, i.e. the development of an 
age-dependent lean phenotype (124). These new opposite findings would certainly lead to a 
higher degree of complexity with regard to the role of AMPK in hypothalamic functions. 
 
 
New insights in AMPK functions from non-mammalian animal model systems 
*Drosophila melanogaster 
Several groups have recently generated AMPK mutants in Drosophila allowing the in vivo 
genetic analysis of AMPK function and identifying new physiological roles. A mutation in the 
AMPK γ-subunit has been described to cause progressive neurodegeneration in Drosophila 
(125). This result further supports emerging role of AMPK in preserving neuronal integrity in 
mammals (126). Deletion of the unique AMPK α-subunit in Drosophila has been also 
generated and showed a lethal phenotype (127, 128), demonstrating the necessity of AMPK 
during embryogenesis as previously shown in mammals. AMPK-null fly embryos showed 
severe abnormalities in epithelial cell polarity with disruption of the apical-basal polarity of 
the actin cytoskeleton. AMPK-null embryos contained defective mitotic divisions leading to 
the frequent formation of polyploid cells. Moreover, AMPK deficient epithelial cells also 
overproliferate under energetic stress forming outgrowths of unpolarirized tumor-like cells. 
Recent results in mammalian cells have demonstrated AMPK-induced repression of cell 
proliferation and cell cycle progression mediated by mTOR and p53 (129, 130). Furthermore, 
the discovery of AMPK activation by the tumor suppressor LKB1 has uncovered a strong 
connection between metabolic signaling, cell proliferation and cancer. Interestingly, LKB1-
null fly mutants showed very similar polarity and mitosis defects to those observed in AMPK-
null mutants (127, 128). Remarkably, expression of a constitutive active form of AMPK 
rescued LKB1-null mutants, suggesting that AMPK is a critical downstream mediator of 
LKB1, controlling mitosis and cell polarity (127, 128). Intriguingly, it has been established 
that myosin II regulatory light chain (MRLC) is a critical downstream target of AMPK for the 
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execution of mitosis and cell polarity establishment both in mammals and Drosophila (127). 
Indeed, expression of an MRLC mutant containing phosphomimetic residues replacing the 
residues phosphorylated by AMPK rescued both cell polarity and mitosis defects in AMPK- 
and LKB1-null fly mutants (127). These findings uncovered a link between energy status and 
cell structures, revealing new pathophysiological functions for AMPK signaling pathway. 
 
*Caenorhabditis elegans 
Senescence in C. elegans is associated with changes in cellular AMP/ATP ratio suggesting a 
link between genes known to affect lifespan and the control of energy metabolism in worms 
(131). Over-expression of the C. elegans AMPKα catalytic subunit increases lifespan (131). 
The generation of mutants in C. elegans has also highlighted the role of AMPK in the 
regulation of lifespan in response to environmental stress and insulin-like signaling (132). 
Environmental stresses such as starvation, heat shock or mutations that inactivate genes 
involved in insulin signaling extend life span only in worms expressing aak-2, which is one of 
the two catalytic subunits of AMPK in C. elegans (131, 133). It has been recently 
demonstrated that AMPK is required for mediating lifespan extension by dietary restriction in 
worms via the phosphorylation of the FOXO transcription factor DAF-16 (134). Interestingly, 
AMPK also phosphorylates human FOXO3 in mammalian cells, indicating that the regulation 
of FOXO by AMPK may be conserved (135). Thus, these studies raise the intriguing 
possibility that AMPK may also be implicated in the increase in life span induced by caloric 
restriction in mammals. Indeed, resveratrol, a polyphenol that activates AMPK, has been 
shown to mitigate effects of high-calorie and high-fat diets in mice by improving lifespan 
(22). 
 
 
Action of anti-diabetic drugs on the AMPK pathway 
Since it has been shown that AMPK could be involved in the anti-diabetic effect of metformin 
(136), numbers of studies have used AMPK activators to investigate putative treatments 
against insulin resistance and diabetes. For example, it has been shown that AMPK activation 
by oligomycin or metformin was able to re-establish a normal insulin-sensitivity in insulin-
resistant cardiomyocytes (137). In this last study, the putative role of AMPK was re-enforced 
by the use of a constitutively active form of AMPK that mimicked the effects of AMPK 
activators. But caution is required when interpreting findings on the sole basis of treatment 
with AICAR, oligomycin or metformin as these widely used pharmacological AMPK 
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activators are not necessarily completely specific for AMPK activation. It has been recently 
demonstrated using mice lacking both α1 and α2 catalytic subunits in the liver that AICAR 
and metformin have detrimental effects on energy metabolism by their inhibition of the 
mitochondrial respiratory-chain complex I independently of AMPK activation (23, 24). These 
results suggest that AICAR and metformin might activate AMPK indirectly by increasing 
cellular AMP/ATP ratio. Significant changes in the cellular AMP/ATP ratio are indeed 
readily detected after treatment of cultured hepatocytes with AICAR and metformin (23, 24) 
and heart perfused with metformin (138). Unlike these non-specific AMPK activators, a direct 
activator A-769662 has been recently identified exerting its cellular effects by direct allosteric 
activation of AMPK activity and not by altering the AMP/ATP ratio (139). In addition to its 
allosteric activation of AMPK, this compound also inhibited the dephosphorylation of Thr 
172 within the α subunit (140). Its specificity as a direct pharmacological activator of AMPK 
has been recently tested on AMPK KO cellular systems validating its use as a valuable 
experimental tool to map new regulatory elements of the AMPK signaling pathway (141). 
 
 
Relationship between adiponectin and AMPK pathways: insights from KO models 
Abundant literature has suggested that adiponectin functions as a protecting factor against the 
development of insulin resistance and diabetes, in part through the activation of AMPK (29, 
142). Therefore, deletion of adiponectin gene or respective receptors could provide valuable 
mice models with impairment of AMPK activation. Comparison of these models with AMPK 
KO mice could raise new interesting data on the consequences of global reduction in AMPK 
activation. Surprisingly, deletion of adiponectin gene is not sufficient to provoke major 
metabolic disorders when fed a standard chow diet (143, 144). However, adiponectin KO 
mice exhibit severe diet-induced insulin resistance when fed a high fat/sucrose diet (145). In 
this model, as long as calorie overloading persists, hypoadiponectinemia and concomitant 
increased in TNF-α levels may drive and aggravate insulin resistance. Contrasting with 
adiponectin KO mice, adiponectin receptor-1 KO mice (AdipoR1 KO mice) showed impaired 
glucose tolerance, increased HGP and insulin resistance when fed a regular chow diet (146, 
147). Abrogation of adiponectin-induced hepatic AMPK activation in AdipoR1 KO mice 
suggested a strong relationship between AMPK and adiponectin pathway mediated through 
adiponectin R1 receptor in the liver (147). According to this result, adiponectin failed to 
regulate hepatic glucose production in liver-specific AMPKα2 KO mice (26). Regarding 
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adiponectin receptor-2 KO mice (AdipoR2 KO mice), opposite phenotypes have been 
published. While one strain of AdipoR2 KO is characterized by a resistance to high-fat 
induced obesity and increased glucose tolerance (146), another strain of AdipoR2 KO mice 
exhibits glucose intolerance and insulin resistance (147). AdipoR2 KO mice did not show 
changes in adiponectin-induced phosphorylation of AMPK in the liver or skeletal muscle 
(146, 147). Thus, changes in AMPK phosphorylation cannot explain different insulin-
responsive phenotype observed in these two AdipoR2 KO models. Alternatively, AdipoR2 
deletion resulted in decreased activity of PPARα signaling pathways in the liver which may 
contribute to reduced insulin sensitivity in these mice (147). These different KO mice models 
indicates that functional differences exist in adiponectin-signaling pathways in the liver, 
AdipoR1 being tightly linked to activation of AMPK pathways whereas AdipoR2 being more 
associated with the activation of PPAR-α pathways (146, 147). However, the link between 
adiponectin and AMPK is more convincing in heart pathologies like hypertrophy. Indeed, it 
has been shown that pressure overload in adiponectin KO mice resulted in enhanced 
hypertrophy associated with a decreased AMPK signaling (148). In cardiomyocytes, 
adiponectin was able to induce AMPK activation concomitantly to the inhibition of an 
agonist-stimulated hypertrophy (148). The fact that the expression of a dominant-negative 
form of AMPK reversed these effects revealed a clear implication of the AMPK signaling in 
the putative adiponectin role as treatment against cardiac hypertrophy. 
 
 
Perspectives 
While the primary targets for AMPK have been involved mainly in the control of energy 
metabolism (16), new evidence indicates that AMPK also participates in the control of non-
metabolic processes such as regulation of mitotic cell division, cell growth, progression 
through the cell cycle and organization of the cytoskeleton. Thus, AMPK signaling pathway 
has evolved into a highly complex system which integrates multiple signals from cellular 
environment to ensure that all highly energy-consuming cellular functions only proceed if 
cells have sufficient metabolic resources. Thus, the key role of AMPK in maintaining energy 
balance places it as an ideal therapeutic target for the treatment of derangements of energy 
metabolism that occur in conditions like obesity, insulin resistance, type 2 diabetes and the 
metabolic syndrome but also cancer. Different specific and non-specific AMPK activators 
have been employed with promising results in animal models with obesity or type 2 diabetes 
(16, 139), but, on the other hand, caution should be exercised for the design of clinical trials. 
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Difficulties in clinical applications may be multifactorial. Experimental animal models are not 
fully reliable and reproduce at least some aspects of human disease. Expression and activation 
pattern of AMPK isoforms differs between rodent and human muscle and between muscle 
fiber types (149, 150). Furthermore, sex difference in muscle AMPK activation has been 
observed in human, probably due to sex specific muscle morphology (higher proportion of 
type 1 muscle fibers in women) (151). Inclusion of these criteria should be accurately 
discussed to better define the population most likely to benefit from AMPK-based therapeutic 
strategies. 
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Figure legends: 
 
Figure 1: AMPKα1α2LS-/- mice are resistant to AICAR hypoglycemic effect. 
AMPKα1α2LS-/- mice deleted for both AMPK catalytic subunit in the liver were obtained by 
crossing liver-specific AMPKα2-/- mice with AMPKα1-/- mice. AICAR tolerance test were 
performed on overnight fasted mice injected intraperitonealy with 0.25 g/kg of AICAR and 
tail blood was collected at 0, 20, 40, 60 and 80 min for determination of glucose concentration 
using a glucometer. **P <0.001, ***P <0.0001 vs. control mice by unpaired, two-tailed 
Student t test. 
 
 
Figure 2: Effect of hepatic AMPKα2-CA expression on glycolytic and lipogenic gene 
expression in the liver of 6hours fasted ob/ob mice. Adenovirus expressing AMPKα2-CA 
(Ad α2-CA) or β-gal (Ad β-gal) were injected in ob/ob and control mice and gene expression 
was analyzed 48 hours post-injection. Each value indicates the amount of mRNA with respect 
to that in 6 hours fasted control C57Bl6J mice, arbitrarily defined as 1. Fold increase is 
indicated below each graph column. *P < 0.05, **P < 0.01, #P < 0.005, ##P < 0.001 vs. 
control mice and $P < 0.05, §P < 0.005, §§P < 0.001 vs. ob/ob Ad β-gal-injected mice. L-PK, 
L-pyruvate kinase; GK, glucokinase; S14, Spot 14 ; SREBP-1, sterol regulatory element–
binding protein-1; ChREBP, carbohydrate response element–binding protein; ACC, acetyl 
CoA-carboxylase; FAS, fatty acid synthase; SCD-1, stearoyl-CoA desaturase-1; GPAT, 
glycerol-3-phosphate acyltransferase. 
 
 
Figure 3: Wheel-running parameters for wild type (Control), and AMPKα2 (AMPKα2-
/-) deficient mice. Parameters are averaged per week. (A) distance per day in km. (B) 
maximal running speed in m per min. (C) number of runs per day. (D) distance per run in 
meters. Running wheels were connected to a DC generator allowing slight loading of the 
wheel (27.10-3 N m at mean maximal speed) and continuous recording of the output voltage 
of the DC generator on a PC computer. Instantaneous speed was calculated from the voltage 
and the resistive load on the DC generator and allowed calculating the distance. These daily 
values were averaged over each week for each animal. Total distance divided by number of 
times (number of runs) gave the distance per run. 
 
 
Figure 4: Role of AMPKα2 in skeletal muscle mitochondrial function. Substrate 
utilization by mitochondria were determined in permeabilized fibers of soleus (A) and 
plantaris (B) muscles of sedentary (SED) and active (ACT) AMPK 2-/- (KO) mice and 
littermate (CT) controls. Respiration rates were measured during the cumulative addition of 
substrates in saponin-skinned cardiac fibers of control and AMPKα2-/- mice. VO2: rate of O2 
consumption in µmol.min-1.g dw-1. G3P: glycerol-3-phosphate, Mal: malate, Oct: octanoyl-
carnitine, Pyr: pyruvate, Glu: glutamate. * p<0.05 vs. control mice. 
 
 
Figure 5: Control of cardiac metabolism during normoxia (A), ischemia (B) and 
reperfusion (C). Under normoxic condition, ATP production comes from fatty acids and 
glucose oxidation. Fatty acids is the privileged substrate (70%) used by the heart, its β-
oxidation inhibiting glucose oxidation via the Randle cycle. Under ischemic condition, 
glycolysis becomes the sole ATP-providing pathway. AMPK plays the role of fuel gauge 
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during this phase. Being activated by the resulting increase in AMP/ATP ratio, AMPK is able 
to promote Glut-4 translocation and PFK-1 stimulation via PFK-2 activation. By stimulating 
glycolysis, AMPK is expected to be protective for the heart during ischemia. During early 
reperfusion, the still existing activated AMPK phosphorylates and inactivates ACC, inducing 
fatty acid entry into mitochondria. This favors fatty acid oxidation to become again the 
principal source for ATP production (80-90%). The concomitant stimulation of glycolysis and 
fatty acid oxidation should induce the uncoupling of glycolysis and glucose oxidation, and, 
so, the detrimental production of protons. 
 
 
Figure 6: Effect of AMPKα2 or LKB1 deletion on glycogen content and lactate 
production in normoxic and ischemic hearts. Hearts were from control (+/+) and knock-out 
(-/-) mice and perfused under normoxic (open bars) or ischemic (solid bars) conditions. 
Values are the means ± SE of at least 5 hearts. *P < 0.05 vs. control mice . 
 
 
Figure 7: Proposed model for the role of AMPK in the hypothalamic control of food 
intake. The activation of AMPK in the hypothalamus during starvation and its inactivation 
upon refeeding are mediated by nutritional changes in circulating hormones and nutrients. 
Ghrelin and adiponectin, which stimulate food intake, activate hypothalamic AMPK, whereas 
glucose, insulin, leptin and presumably resistin, which are known to inhibit food intake, 
inhibit it. Once activated, AMPK phosphorylates and inactivates ACC. The expected 
consequences are elevated malonyl-CoA concentration, leading to subsequent inhibition of 
mitochondrial fatty acid oxidation, and increased level of LCFA-CoA. The hypothalamic 
integration of these signals results in opposite changes in orexigenic/anorexigenic 
neuropeptides expression and subsequent modification of food intake. The underlying 
mechanism(s) upstream and downstream AMPK remain to be identified. ACC, acetyl-CoA 
carboxylase; ACS, acyl-CoA synthetase; AMPK, AMP-activated protein kinase; CPT-1, 
carnitine palmitoyl transferase 1; FAS, fatty acid synthase; MCD, malonyl-CoA 
decarboxylase; mTOR, mammalian target of rapamycin. 
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Table 1A: Genetic animal models for the study of AMPK signaling pathway. 
 
 
Animal model Tissue specificity Remarks Reference 
    
Knock-out mice    
AMPKα1 whole-body  (17) 
AMPKα2 whole-body  (18) 
AMPKβ1 whole-body  (B. Kemp)* 
AMPKβ2 whole-body  (B. Kemp)* 
AMPKγ3 whole-body  (65) 
    
Alfpα2 liver use of Alfp-Cre (26) 
α1KOAlfpα2 whole-body α1 and liver α2 use of Alfp-Cre (24) 
AgRPα2 hypothalamus (AgRP neurons) use of AgRp-Cre (124) 
POMCα2 hypothalamus (POMC neurons) use of POMC-Cre (124) 
α1KOPOMCα2 whole-body α1 and POMC α2 use of POMC-Cre (124) 
    
Muscle/heart LKB1 skeletal and cardiac muscle  use of MCK-Cre (7, 8, 152) 
    
Transgenic mice    
AMPKα1R45A skeletal and cardiac muscle MCK promoter/ AMPK-DN (64) 
AMPKα2D157A skeletal and cardiac muscle MCK promoter/ AMPK-DN (64) 
AMPKα2R45A skeletal and cardiac muscle MCK promoter/ AMPK-DN (19) 
AMPKα2D157A heart α-MHC promoter/ AMPK-DN (85) 
    
AMPKγ1R70Q skeletal muscle α-actin promoter/ AMPK-CA (77) 
    
AMPKγ2 heart α-MHC promoter (87, 88) 
AMPKγ2R302Q heart α-MHC promoter/ AMPK-CA (87) 
AMPKγ2N488I heart α-MHC promoter/ AMPK-CA (88, 89) 
AMPKγ2T400N heart α-MHC promoter/ AMPK-CA (91) 
AMPKγ2R531G heart α-MHC promoter/ AMPK-CA (90) 
    
AMPKγ3 skeletal and cardiac muscle  MCK promoter (65, 76) 
AMPKγ3R225Q skeletal and cardiac muscle  MCK promoter/ AMPK-CA (65, 76) 
    
Adenovirus-mediated 
gene transfer 
   
Liver AMPKα2-CA liver Ad AMPKα2-CA infection (21) 
Neuron AMPKα1-CA 
Neuron AMPKα1+α2-DN 
 
Liver LKB1 KO 
hypothalamus 
hypothalamus 
 
liver 
Ad AMPKα1-CA infection 
Ad AMPKα1+α2-DN infection 
 
Ad Cre infection 
(107) 
(107) 
 
(27) 
 
Ad, adenovirus; Alfp, albumin α-fetoprotein; AgRP, agouti-related protein; Cre, Cre recombinase; MCK, muscle 
creatine kinase; POMC, pro-opiomelanocortin; α-MHC, α-myosin heavy chain; AMPKα1-CA, AMPKα1 
constitutively active form; AMPKα2-CA, AMPKα2 constitutively active form; AMPKα1+α2-DN, 
AMPKα1and AMPKα2 dominant negative forms. 
* Bruce Kemp, personal communication. 
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Table 1B: Validation of AMPK pathways in transgenic and knock-out mouse models. 
 
 
Organ/tissue Pathway/function Animal model Reference 
    
Heart Glycogen storage cardiomyopathy 
 
Tg AMPKγ2R302Q 
Tg AMPKγ2N488I 
Tg AMPKγ2R531G 
Tg AMPKγ2T400N 
(87) 
(88, 89) 
(90) 
(91) 
 Ischemic/post-ischemic tolerance AMPKα2 KO 
Tg AMPKα2R45A 
Tg AMPKα2D157A 
 
(82, 84) 
(83) 
(85) 
 Glucose transport, glycogen metabolism, 
glycolysis 
 
 
AMPKα2 KO 
Tg AMPKα2R45A 
Tg AMPKα2D157A 
 
(82, 84) 
(83) 
(85) 
 Mitochondrial biogenesis/ function 
 
Tg AMPKα2R45A 
AMPKα2 KO 
 
(95) 
(95) 
Skeletal muscle Glucose transport Tg AMPKα2R45A 
Tg AMPKα2D157A 
AMPKα2 KO 
(6, 19) 
(85) 
(6) 
 Contraction/exercise tolerance Tg AMPKα2R45A 
Tg AMPKα2D157A 
Tg AMPKγ1R70Q 
Tg AMPKγ3R225Q 
(19) 
(43, 51) 
(51, 77) 
(65, 71) 
 Glycogen metabolism Tg AMPKγ3R225Q 
Tg AMPKγ1R70Q 
AMPKγ3 KO 
(65, 76) 
(77) 
(65) 
 Mitochondrial biogenesis/ function 
 
Tg AMPKα2R45A 
AMPKα2 KO 
 
(52) 
(44, 45, 153) 
Liver Hepatic glucose production Alfpα2 KO (26) 
 Mitochondrial biogenesis/ function 
 
α1KOAlfpα2 (23) 
Blood vessels eNOS activation AMPKα1 KO (96) 
 Vasorelaxation 
 
AMPKα1 KO (102) 
Adipose tissue Lipolysis AMPKα1 KO (37) 
 Fat mass/ morphology AMPKα1 KO 
AMPKα2 KO 
Liver AMPKα2-CA 
(37) 
(38) 
(21) 
Brain Food intake 
 
 
 
AgRPα2 
POMCα2 
Neuron AMPKα1-CA 
Neuron AMPKα1/α2-DN 
(124) 
(124) 
(107) 
(107) 
 Neuroprotection/stroke POMCα2 (126) 
 
Tg, transgenic mice; KO, knock-out mice; AMPKα1-CA, AMPKα1 constitutively active form AMPKα2-CA, 
AMPKα2 constitutively active form; AMPKα1+α2-DN, AMPKα1and AMPKα2 dominant negative forms. 
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Table 2: Body weight, food intake, 24h-respiratory quotient and energy expenditure in 
AMPKα1-/- and AMPKα2-/- mice during fasted and fed periods. 
 
 
 24h-FASTED  FED 
      
 control AMPKα1-/-  control AMPKα1-/- 
      
Body weight (g) 30±1 31±1  30±1 31±1 
      
Food intake 
(g/day) 
- -  4.7±0.1 4.8±0.1 
      
Energy 
expenditure 
(mean/24H) 
168±6 175±5  245±11 246±7 
      
24h-respiratory 
quotient 
(VCO2/VO2) 
0.77±0.01 0.77±0.01  0.98±0.03 0.96±0.03 
      
 control AMPKα2-/-  control AMPKα2-/- 
      
Body weight (g) 32±1 31±1  31±1 31±1 
      
Food intake 
(g/day) 
- -  3.8±0.1 3.7±0.1 
      
Energy 
expenditure 
(mean/24H) 
207±6 205±3  259±6 264±8 
      
24h-respiratory 
quotient 
(VCO2/VO2) 
0.88±0.01 0.89±0.01  0.93±0.01 0.94±0.01 
 
Values are means ± S.E.M. in
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Table 3: Mitochondrial respiration on control and AMPK 2-/- muscles. Values are means ± 
S.E.M. Oxygen consumption rates in the absence (V0) and presence of 2mmol/l ADP (Vglu+mal respiration 
through complex I with glutamate+malate; Vsuc respiration through complex II with succinate). Michaelis-
Menten constant of respiration rate for ADP (µmol/l) without (Km) or with (KmCr) 20mmol/l creatine. ACR: 
acceptor control ratio (Vglu+mal/V0). * p <0.05 versus control mice.  
 
 
 Soleus Plantaris 
 CT AMPK 2-/- CT AMPK 2-/- 
Animals (n) 
Fibers (n) 
V0 (µmol O2.min
-1.g-1dw) 
9 
9 
1.8 ± 0.5 
8 
8 
1.3 ± 0.2 
9 
18 
1.5 ± 0.2 
8 
16 
1.7 ± 0.3 
Vglu+mal (µmol O2.min
-1.g-1dw) 9.8 ± 1.4 9.9 ± 1.4 7.8 ± 0.6 7.7 ± 0.9 
Vsuc (µmol O2.min
-1.g-1dw) 6.3 ± 1.7 7.3 ± 1.3 4.6 ± 0.3 5.5 ± 0.7 
KmADP (µM) 246 ± 54 224 ± 57 233 ± 30 406 ± 61 
KmADP+Cr (µM) 98 ± 19 80 ± 13 93 ± 12 126 ± 20 
ACR 7.7 ± 1.6 8.5 ± 1.2 6.8 ± 1.1 4.6 ± 0.3 
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Fig5A.jpg 
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Fig5B.jpg 
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Fig5C.jpg 
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Fig6.jpg 
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Fig7.jpg 
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